Open Government Portal

About this information

Open data is defined as structured data that is machine-readable, freely shared, used and built on without restrictions.

The key things to remember about open data are:

  • #Availability and access#: the data must be available as a whole and at no more than a reasonable reproduction cost, preferably by downloading over the internet. The data must also be available in a convenient and modifiable form.
  • #Re-use and redistribution#: the data must be provided under terms that permit re-use and redistribution including the intermixing with other datasets.
  • #Universal participation#: everyone must be able to use, re-use and redistribute. There should be no discrimination against fields of endeavour or against persons or groups. For example, 'non-commercial' restrictions that would prevent 'commercial' use, or restrictions of use for certain purposes (e.g. only in education), are not allowed.
47529 records

Health Canada carried out a safety review to look into the use of atypical antipsychotics and the potential risk of …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review atypical antipsychotics assessing potential risk Urinary Retention difficulty urinating new safety information manufacturer Seroquel (quetiapine)

Health Canada reviewed the potential risk of colitis with Aubagio use after finding reports (since being marketed) of colitis as …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review AUBAGIO (teriflunomide) assessing potential risk inflammation of the colon colitis risk of colitis product safety information a closely-related drug Arava (leflunomide) new-warning for colitis

The Canadian product safety information for lorazepam and midazolam warn that they should not be used during pregnancy. The Canadian …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Benzodiazepines barbiturates assessing potential risk negative effects development of children’s-brains neurodevelopmental disorders lorazepam midazolam phenobarbital during pregnancy ...

Health Canada reviewed the potential risk of severe bone damage (osteonecrosis) with bisphosphonate use because of product information updates in …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Bisphosphonates assessing potential risk Severe Bone Damage osteonecrosis product information ear canal jawbone damage

Health Canada has completed a safety review on the potential risk of BIA-ALCL, following an increase in the number of …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Breast Implants assessing potential-risk of cancer Breast-implant associated-anaplastic large-cell-lymphoma BIA-ALCL

Health Canada carried out a safety review of all the available evidence to evaluate the risk of side effects related …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Celecoxib safety review assessing heart-and-stroke side effects high doses Non-Steroidal Anti-Inflammatory Drugs NSAIDs diclofenac ibuprofen naproxen

Clozapine is a prescription drug authorized for sale in Canada to manage symptoms of schizophrenia when other drugs have not …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Clozapine assessing effectiveness monitoring white-blood-cells levels low-numbers of white-blood-cells agranulocytosis symptoms of schizophrenia life-threatening infections-and-deaths patient registry program

Codeine is converted to morphine in the liver. Some people have genetic variations of liver enzymes which cause codeine to …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review CODEINE assessing breathing problems children and adolescents liver liver enzymes genetic differences ultra-rapid metabolizers

In 2013 and 2015, Health Canada carried out safety reviews on codeine-containing products as they relate to the risk of …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Codeine-containing products assessing serious breathing problems Children and Adolescents treated with codeine

A safety review was carried out after Health Canada received a report from the European Medicines Agency, which linked hearing …

Record Modified: May 8, 2024
Record Released: May 6, 2024
Publisher: Health Canada
Formats: HTML
Keywords: Summary Safety Review Denosumab Prolia Xgeva hearing loss deafness